NCT04730388Unknown不适用
Evaluation of the Efficacy and Tolerance of the Association ATEZOLIZUMAB - BEVACIZUMAB in the Treatment of a Locally Advanced Hepatocellular Carcinoma Inoperable or Metastatic in Finistère
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 100
- 主要终点
- predictive factor for progression-free survival
研究概览
简要总结
Evaluation of the efficacy and safety of the combination ATEZOLIZUMAB - BEVACIZUMAB in the treatment of locally advanced inoperable or metastatic hepatocellular carcinoma in Finistère
详细描述
Patients treated by ATEZOLIZUMAB and BEVACIZUMAB for an Advanced hepatocellular carcinoma will be followed to observed their safety and the efficacy of this treatment, and to identify prongnosis factors
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •hepatocellular carcinoma locally advanced or metastatic, non able to be resectable, with no prior systemic treatment
- •Child Pugh A and ECOG 0 or 1
- •upper digestiuve endoscopy less than 6 months, if esophageal varcices : must be treated
- •non eligible to receive a locoregional therpay or progressive after this kinf of treatment
- •with informed consent
排除标准
- •refuse to participate
- •under legal protection
- •exclusion criteria from the tempory utilisation authorization
结局指标
主要结局
predictive factor for progression-free survival
时间窗: 12 months
progression-free survival = time between treatment initiation and rediologic or clinical progression
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal MelanomaMelanomaNCT04091217Hoffmann-La Roche43
招募中
1 期
Atezolizumab+Bevacizumab+SBRT in Unresectable HCCUnresectable Hepatocellular CarcinomaNCT05096715Massachusetts General Hospital20
尚未招募
不适用
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world StudyHCCNCT06024252Zhongda Hospital200
撤回
1 期
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin LymphomaLymphoma, Non-HodgkinNCT03369964Hoffmann-La Roche
已完成
3 期
A phase III study of atezolizumab in patients with hepatocellular carcinomaHepatocellular carcinomaJPRN-jRCT2080223820CHUGAI PHARMACEUTICAL CO., LTD.501